GSK Gets RSV Vaccine Expansion To Younger Adults

Arexvy was approved by the US FDA for adults 50-59 with medical conditions that put them at increased risk of severe RSV. Separately, the company ended a cancer deal with SpringWorks.

GSK received an FDA approval for Arexvy • Source: Shutterstock

GSK plc has scored a notch on the respiratory syncytial virus (RSV) vaccine development leaderboard, beating rival Pfizer Inc. to a younger adult population. The US Food and Drug Administration on 7 June approved GSK’s RSV vaccine Arexvy in adults aged 50-59 who have medical conditions that put them at increased risk of severe RSV.

Key Takeaways

  • GSK beat Pfizer to a new younger patient population for its RSV vaccine Arexvy with US FDA approval in adults aged 50-59.

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is expected to discuss vaccination recommendations...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip